Pepsi got its pink on. So did Yoplait, the MLB and Kroger. Even Mike’s Hard Lemonade went pink, although breast cancer advocates found that one a little hard to swallow.
Why? Cause marketing … it’s in vogue, says Martin Smith in an article for Technorati. For-profits working hand-in-hand with non-profits means everyone’s a winner, right?
Not always. The charity from Mike’s Hard Lemonade was shunned by the breast cancer community even though the company has given $500,000 to the Breast Cancer Foundation during the past two years from sales of its pink drink.
On the other hand, Yoplait has given $30 million for breast cancer during the past 13 years and is enjoying a successful and profitable partnership with Susan G. Komen for the Cure. Kroger, in partnership with Campbell’s and several other manufacturers have raised about $3 million annually to support breast cancer research, education, prevention and awareness. And the MLB Charities has committed $50,000 to Komen for the Cure through the "Going to Bat Against Breast Cancer" program. That's in addition to the proceeds raised from auctioning pink equipment players used during games on Mother’s Day weekend.
Smith purposes several reasons for-profit companies would want on the pink bandwagon. Tax breaks didn’t make the list. Increased profits did, but it came in last place of purposed concepts that included ideas such as increased relevance, greater trust, rallying employees and empowering brand advocates. The latter caught my attention with Smith’s parenthetical explanation of “something to tweet, link, blog.”
Case in point: Huge, an interactive ad agency, created an entire digital initiative for Pepsi’s Refresh Everything project that has paid off hugely for the soda conglomerate. Breast cancer is among the many initiatives vying for millions in support Pepsi is giving away. To date, the project has gained 3 billion earned media impressions, the number of Facebook fans increased tenfold to more than 3 million, and Pepsi jumped to the No. 5 spot among the country's most reputable brands.
So have we all, as opponents purpose, been “pinkwashed?”
Maybe so. Yes, the companies are profiting, but so is the cause.
Thursday, June 9, 2011
Tuesday, June 7, 2011
Is there an obligation to continue the conversation?
I was introduced recently via Alltop to Lillie Shockney’s Breast Cancer Chronicles. Shockney is a nurse and administrative director of Johns Hopkins Avon Foundation Breast Center. She also is a breast cancer survivor. Her blog is published on Yahoo! Health.
Supporting a blog is not only a good way for Johns Hopkins to promote health care, but it can also serve as an avenue to further establish the institution as an industry leader. Shockney’s blog discloses upfront her relationship with the breast center as well as her own experiences with the disease — establishing her not only as an expert in the field but also one that brings to the table an element of empathy.
She combines those attributes nicely in a May 19 entry titled, “Taking Tamoxifen to Prevent Breast Cancer Really Pays Off!” Shockney presents straightforward information — the good, bad and ugly — about tamoxifen, a drug prescribed for the prevention of breast cancer to women who are at a high risk for the disease.
Her blog resonates nicely for the Johns Hopkins brand. It provides reputable information in an easy to understand format and gives a sense that Shockney truly relates to the battle with breast cancer on a personal level and as a health care provider. In a way, the blog provides a human touch to the concept of being treated in a hospital, which can sometimes feel cold and clinical.
Here is a woman who knows her stuff and can truly relate to what she writes about.
But given the comments Shockney leaves readers with regarding the “nasty side effects of tamoxifen,” I think she has an obligation to continue the conversation. The news coming out of the 2011 American Society of Clinical Oncology provides the opportunity. Discussed were aromatase inhibitors, which like tamoxifen, can prevent breast cancer, according to reports from ABC news.
Could these be a viable option for the "next steps" Shockney writes about at the end of the blog post? Surely patients at the Avon Breast Center will ask her about them. Why not continue the conversation here as well?
Subscribe to:
Posts (Atom)